CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 30 enrolled / 30 target
Drug / intervention
Belantamab mafodotin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07217184
NCT07217184Phase 1ActiveUpdate Overdue (0.5/mo)Completion was 14mo ago
CompareCT.gov

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination

GlaxoSmithKline·interventional·Posted Oct 15, 2025·Updated Jun 25, 2026

In Brief

A Phase 1 clinical trial evaluating Belantamab mafodotin and Isatuximab for Multiple Myeloma. Active but no longer recruiting, targeting 30 participants across 19 sites in 11 countries.

Signals

Enrollment appears stalled

Detailed Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Brazil, Canada, France, Greece, Mexico, Norway, South Korea, Spain, Sweden, United States
Collaborators--

Timeline

Phase 1Active
202220232024202520262027
First PostedOct 15, 2025
Enrollment StartJul 29, 2021
Primary CompletionApr 17, 2025
Study CompletionMar 11, 2027
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9 months ago

Arms & Interventions

Belantamab mafodotin + Isatuximabexperimental

Drug: Belantamab mafodotinDrug: Isatuximab

Interventions

Belantamab mafodotindrug

Belantamab mafodotin will be administered.

Isatuximabdrug

Isatuximab will be administered.